Syndax Revenue Jumps 82% To $83.3 Million, Yet Stockholders' Equity Slips Into A $17.2 Million Deficit

Royalty financing and new convertible notes outweigh a $551.1 million cash and investments pile on Syndax's balance sheet.

Share
Syndax Revenue Jumps 82% To $83.3 Million, Yet Stockholders' Equity Slips Into A $17.2 Million Deficit

Syndax Pharmaceuticals, a commercial-stage company developing cancer therapies, posted third-quarter revenue of $83.3 million, up 82% from a year earlier, yet its 10-Q shows stockholders' equity at a deficit of $17.2 million on September 30. Equity stood at a $15.1 million surplus on June 30 and $64.6 million at the end of 2025.

Liabilities pass assets

Total liabilities reached $709.9 million against total assets of $692.7 million, even with cash, cash equivalents and investments of $551.1 million. At year-end 2025, liabilities were $465.1 million against assets of $529.7 million.

Two items drive the gap. The royalty-interest financing liability tied to Niktimvo stands at $344.1 million, and the convertible note liability, new this year, is $244.2 million. Accrued interest on the royalty financing was $37.7 million, up from $25.5 million at December 31.

The accumulated deficit is $1.6 billion. Net loss for the quarter was $49.4 million, or $0.55 per share, versus $60.7 million a year earlier.

How the debt got there

In November 2024, Syndax sold Royalty Pharma the right to 13.8% of quarterly U.S. Niktimvo net sales for $350.0 million up front. Total payments to Royalty Pharma are capped at $822.5 million, or 2.35 times the funded amount.

In June 2026 it issued $250.0 million of 2.25% convertible senior notes due 2031. The initial conversion price is about $24.76 per share, and the notes could convert into as many as 13,631,400 shares at the maximum rate. Their first interest payment is due December 15, 2026, and cash interest will total $5.7 million a year.

Financing inflows were $263.9 million for the first nine months, and net cash used in operations fell to $107.9 million from $253.5 million.

Two drugs, both growing

Revuforj, an oral menin inhibitor for certain relapsed or refractory acute leukemias, brought in $60.7 million, up 90% from a year earlier and 11% from the second quarter. New patients rose about 20% and total prescriptions about 13% from the second quarter.

Niktimvo, sold with partner Incyte for chronic graft-versus-host disease, had net revenue of $67.4 million, up 47% from a year earlier and 12% from the second quarter. Syndax's half of the profit, booked as collaboration revenue, was $22.6 million.

Cost of product sales rose to $14.0 million from $2.1 million a year earlier, partly from a one-time $10.0 million milestone owed to AbbVie after Revuforj sales passed $150.0 million. Research spending rose to $67.5 million from $56.3 million.

An axatilimab trial in idiopathic pulmonary fibrosis missed its main goal, and Syndax does not plan further development in that disease.

A new finance chief

In an 8-K filed Monday, Syndax said CFO Keith Goldan will retire effective November 9. Aaron Ondrey, most recently CFO of Beren Therapeutics, takes the role that day.

Syndax says it still expects 2026 research plus administrative spending of about $400 million, excluding $50 million of non-cash stock compensation. It says its cash and expected revenue will enable it to reach profitability.

Syndax had $157.9 million left under its at-the-market stock program at quarter-end and sold no shares under it in the quarter.

Sources